Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of TAP-144-SR (6M) vs TAP-144-SR (3M) in prostate cancer
jRCT2080221721Phase 3
- Sponsor
- Takeda
- Start
- Feb 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of leuprolide in prostate cancer (PCa) (2 arms), sponsored by Takeda. Primary endpoints: Hormone dynamics, Pharmacokinetics and 2 more.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2080221721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221721.